BO-112 Plus Pembrolizumab for Patients With Anti–PD-1–Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203
The clinical trial has met its primary end point (ORR) making BO-112 with pembrolizumab a potential strategy to revert anti-PD-1 resistance in patients with MEL. PFS results are in line with other clinical trials in anti-PD-1-resistant scenario, with promising OS data.
Authors
- Beatriz García‐Peláez
- Ana Arance (ORCID: https://orcid.org/0000-0003-2896-1957)
- S. Prey (ORCID: https://orcid.org/0000-0003-0272-2640)
- Sonia Rodrı́guez (ORCID: https://orcid.org/0000-0002-5878-9089)
- Luis de la Cruz‐Merino (ORCID: https://orcid.org/0000-0002-5333-0535)
- Miguel F. Sanmamed (ORCID: https://orcid.org/0000-0002-7295-6074)
- Ignacio Melero (ORCID: https://orcid.org/0000-0002-1360-348X)
- Philippe Saïag (ORCID: https://orcid.org/0000-0002-6500-3507)
- Marya Chaney (ORCID: https://orcid.org/0000-0001-6820-7081)
- Elisa Funck‐Brentano (ORCID: https://orcid.org/0000-0002-1092-0789)
- Henri Montaudié (ORCID: https://orcid.org/0000-0002-0528-4829)
- Juan F. Rodríguez-Moreno
- Marisol Quintero (ORCID: https://orcid.org/0000-0002-4330-8393)
- Zuzana Jirakova Trnkova
- Caroline Dutriaux (ORCID: https://orcid.org/0000-0002-9836-5168)
- M.P. Lopez Criado
- Iván Márquez‐Rodas (ORCID: https://orcid.org/0000-0002-2476-668X)
- María González‐Cao (ORCID: https://orcid.org/0000-0003-3791-540X)
- Stéphane Dalle (ORCID: https://orcid.org/0000-0002-3423-4548)
- J. Charles (ORCID: https://orcid.org/0000-0003-4667-6009)
- Ma Carmen Álamo de la Gala
- Caroline Robert (ORCID: https://orcid.org/0000-0002-9493-0238)
- Pablo Cerezuela (ORCID: https://orcid.org/0000-0002-4886-4831)
- Enrique de Miguel (ORCID: https://orcid.org/0000-0002-9254-6187)
- Alfonso Berrocal (ORCID: https://orcid.org/0000-0001-9733-6755)
- Jose Antonio Avilés‐Izquierdo
- Ruth Román
- Eduardo Castañón Álvarez (ORCID: https://orcid.org/0000-0003-2957-4414)
- Sonia Maciá
Institutions
- Université Claude Bernard Lyon 1 (FR)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Université de Versailles Saint-Quentin-en-Yvelines (FR)
- Université Paris-Saclay (FR)
- Centre Hospitalier Universitaire de Grenoble (FR)
- Institut Gustave Roussy (FR)
- Hospital General Universitario Gregorio Marañón (ES)
- Centre Hospitalier Universitaire de Bordeaux (FR)
- Centre Hospitalier Universitaire de Nice (FR)
- Hospital Universitario Virgen Macarena (ES)
- Instituto Oncológico Dr. Rosell (ES)
- Assistance Publique – Hôpitaux de Paris (FR)
- Hospices Civils de Lyon (FR)
- Centre Léon Bérard (FR)
- Hospital Clínic de Barcelona (ES)
- HM Hospitales (ES)
- Centre de Recherche en Cancérologie de Lyon (FR)
- Hospital General Universitario De Valencia (ES)
- Hôpital Ambroise-Paré (FR)
- Instituto de Biomedicina de Sevilla (ES)
- Clinica Universidad de Navarra (ES)
- Highlight Therapeutics (Spain) (ES)
- Instituto Murciano de Investigación Biosanitaria (ES)
- Centro de Investigación Biomédica en Red de Cáncer (ES)
- MD Anderson Cancer Center Madrid (ES)
- Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
- Biomarqueurs et essais cliniques en Cancérologie et Onco-Hématologie (FR)
- Universidad de Sevilla (ES)
- Université Grenoble Alpes (FR)
Publication Details
- Journal
- Journal of Clinical Oncology
- Published
- 2025-06-27
- DOI
- https://doi.org/10.1200/jco-24-02595
- Citations
- 3
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 3.14